A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
Clinical trial NCT05048342 · COMPLETED
Trial details
- NCT number
- NCT05048342
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-15
- Primary completion
- 2023-12-08
- Enrollment
- 71
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.